1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Global Biopharmaceuticals Market Size, Share, Development, Growth and Demand Forecast to 2020- Industry Insights by Type and by Application

The global biopharmaceuticals market accounted for $ 160,440.4 million in 2014, and it is expected to grow with a CAGR of 9.6% during 2015-2020. The monoclonal antibodies market segment dominated the global biopharmaceuticals market in 2014 with about 25.8% share; whereas, among application segment, the oncology segment accounted for the highest share of 27% in the global biopharmaceuticals market in the same year. The global biopharmaceuticals market is growing with a high growth rate, due to increasing geriatric population, increasing R&D investments, increasing prevalence of chronic diseases, and technological advancements in biopharmaceuticals which has helped in curing diseases with no available treatment.

Biopharmaceuticals are in huge demand due to the increasing prevalence of chronic diseases, which is one of the key drivers, fuelling the growth of the global biopharmaceuticals market. Chronic diseases are increasing due to unhealthy lifestyle, poor diet, excess alcohol consumption, and lack of physical activity. The increase in chronic diseases worldwide is leading to the growth in the number of hospitalization cases, which is fuelling the demand for biopharmaceuticals. The monoclonal antibodies market grew with an average annual growth rate of over 9.3% during 2011-2014. The oncology market on the other hand, grew with a CAGR of 10.9% during 2011-2014.

The R&D investments in formulation and development of a drug have increased, due to the growing demand for prevention, treatment, and complete curative options for various diseases. Many pharmaceutical companies are focusing on developing more effective products to treat life-threatening diseases and encourage patients to live healthier lives with reduced disabilities. The increasing healthcare investments around the world, is propelling the increase in R&D investments, which is fuelling the growth of the global biopharmaceuticals market.

The increasing aging population is propelling the growth of the global biopharmaceuticals market, as the pool of elder population is more prone to illness due to low immunity levels, and high recovery time consumption. The elderly people are also susceptible to dermatological disorders, such as dermatitis and cellulitis. Moreover, common eye diseases, including glaucoma and age-related macular degeneration (AMD) are also age-related diseases. These age-related disorders would require more effective biopharmaceuticals for their treatment, thus fuelling the demand of the global biopharmaceuticals market.

The technological advancements in biopharmaceuticals, such as target specific approach with high efficiency, are proving to be advantageous in treating various disorders and chronic diseases. Additionally, biopharmaceuticals have the potential to prevent, treat, and heal the diseases completely, which are otherwise difficult to cure or have no available treatment.

The restraints associated with the global biopharmaceuticals market include high cost of biopharmaceuticals and side effects, such as breathing problems, sore throat, allergic reactions, itching, and rashes due to the consumption of biopharmaceuticals. The low-cost biosimilars are posing a threat to the global biopharmaceuticals market. Biosimilar refers to a biological product that is approved by drug related authorities, such as the Food Drug Association (FDA) and is similar in function, safety, and effectiveness; just like the original product manufactured by a different company. Furthermore, the easy availability of low-priced biosimilars of existing biopharmaceuticals is hampering the growth of the global biopharmaceuticals market.

The key companies operating in the global biopharmaceuticals market include AbbVie Inc, Eli Lilly and Company, Sanofi, Pfizer Inc., Abbott Laboratories, AstraZeneca PLC, Novartis AG, Biogen Idec , Bristol-Myers Squibb Company, and Amgen Inc.



Report Coverage

Provides comprehensive understanding of the market with the help of informed market outlook, opportunities, challenges, trends, size and growth, competitive analysis, major competitors and Porter analysis
Identifies the key drivers of growth and challenges of the key industry players. Also, assesses the future impact of the propellants and restraints on the market
Uncovers potential demands in the market
Porter analysis identifies competitive forces within the market
Provides information on the historical and current market size and the future potential of the market
Provides sizes of key regional markets using yardsticks of processes, segments, products, end user and technology, etc (as applicable)
Highlights the competitive scenario of the market, major competitors, market share, benchmarking, investments and merger acquisitions
Provides profiles of major competitors of the market including details of their operations, product and services, recent developments and key financial metrics. Profiles provide better understanding of competition as well as the demands of the market.

Table Of Contents

Global Biopharmaceuticals Market Size, Share, Development, Growth and Demand Forecast to 2020- Industry Insights by Type and by Application
Chapter 1. Research Scope and Methodology

1.1 Market Definition

1.2 Market Scope

1.2.1 Global biopharmaceuticals market breakdown by type

1.2.2 Global biopharmaceuticals market breakdown by application

1.2.3 Global biopharmaceuticals market breakdown by geography

1.3 Research Methodology and Sources

Chapter 2. Executive Summary

2.1 Key Findings

2.2 Research Summary

Chapter 3. Market Outlook

3.1 Introduction

3.2 Market Trend

3.2.1 Outsourcing of research and production of biopharmaceuticals

3.3 Factors Driving the Market and its Impact on Market Forecast

3.3.1 Increasing prevalence of chronic diseases

3.3.2 Increasing RandD investments

3.3.3 Growing aging population

3.3.4 Technological advancements in biopharmaceuticals

3.3.5 Impact analysis of drivers on market forecast

3.4 Factors Hindering the Market and its Impact on Market Forecast

3.4.1 High cost of biopharmaceuticals

3.4.2 Entry of low-cost biosimilars in the market

3.4.3 Side effects associated with biopharmaceutical drugs

3.4.4 Impact analysis of restraints on market forecast

Chapter 4. Global Biopharmaceuticals Market Size and Forecast (2011 - 2020)

4.1 Global Biopharmaceuticals Market Breakdown by type

4.2 Global Biopharmaceuticals Market Breakdown by Application

4.3 Global Biopharmaceuticals Market Breakdown by Region

Chapter 5. Global Biopharmaceuticals Market Breakdown by Type

5.1 Monoclonal Antibodies Market

5.2 Recombinant Human Insulin Market

5.3 Colony Stimulating Factor Market

5.4 Erythropoietin Market

5.5 Vaccines Market

5.6 Growth Hormones Market

5.7 Interferons Market

5.8 Recombinant Proteins Market

5.9 Purified Proteins Market

5.10 Others

Chapter 6. Global Biopharmaceuticals Market Breakdown by Application

6.1 Oncology Biopharmaceuticals Market

6.2 Inflammatory and Infectious Diseases Biopharmaceuticals Market

6.3 Metabolic Disorders Biopharmaceuticals Market

6.4 Neurological Disorders Biopharmaceuticals Market

6.5 Cardiovascular Diseases Biopharmaceuticals Market

6.5.1 Other Applications

Chapter 7. Global Biopharmaceuticals Market Breakdown by Geography

7.1 North America Biopharmaceuticals Market

7.1.1 North America biopharmaceuticals market breakdown by type

7.1.2 North America biopharmaceuticals market breakdown by application

7.1.3 North America biopharmaceuticals market breakdown by country

7.2 Europe Biopharmaceuticals Market

7.2.1 Europe biopharmaceuticals market breakdown by type

7.2.2 Europe biopharmaceuticals market breakdown by application

7.2.3 Europe biopharmaceuticals market breakdown by country

7.3 Asia Biopharmaceuticals Market

7.3.1 Asia biopharmaceuticals market breakdown by type

7.3.2 Asia biopharmaceuticals market breakdown by application

7.3.3 Asia biopharmaceuticals market breakdown by country

7.4 Rest of the World Biopharmaceuticals Market

7.4.1 Rest of the world biopharmaceuticals market breakdown by type

7.4.2 Rest of the world biopharmaceuticals market breakdown by application

7.4.3 Rest of the world biopharmaceuticals market breakdown by country

Chapter 8. Competitive Analysis and Market Share

8.1 Porter's Five Forces of Competitive Position Analysis

8.1.1 Bargaining power of buyers

8.1.2 Bargaining power of suppliers

8.1.3 Threat of new entrants

8.1.4 Intensity of rivalry

8.1.5 Threat of substitutes

8.2 Market Share Analysis of Major Players

Chapter 9. Company Profiles and Strategic Developments

9.1 Key Company Profiles

9.1.1 AbbVie Inc.

9.1.1.1 Business overview

9.1.1.2 Products and services

9.1.2 Sanofi

9.1.2.1 Business overview

9.1.2.2 Products and services

9.1.3 Eli Lilly and Company

9.1.3.1 Business overview

9.1.3.2 Products and services

9.1.4 Pfizer Inc.

9.1.4.1 Business overview

9.1.4.2 Products and services

9.1.5 Abbott Laboratories

9.1.5.1 Business Overview

9.1.5.2 Products and services

9.1.6 AstraZeneca PLC

9.1.6.1 Business overview

9.1.6.2 Products and services

9.1.7 Novartis AG

9.1.7.1 Business Overview

9.1.7.2 Products and services

9.1.8 Biogen Idec

9.1.8.1 Business overview

9.1.8.2 Products and services

9.1.9 Amgen Inc.

9.1.9.1 Business Overview

9.1.9.2 Products and services

9.1.10 Bristol-Myers Squibb Company

9.1.10.1 Business overview

9.1.10.2 Products and services

9.1.11 Glaxo Smith Kline PLC

9.1.11.1 Business overview

9.1.11.2 Products and services

9.1.12 Johnson and Johnson Services Inc.

9.1.12.1 Business Overview

9.1.12.2 Products and Services

9.1.13 F. Hoffmann-La Roche Ltd.

9.1.13.1 Business overview

9.1.13.2 Products and services

9.1.14 Merck and Co. Inc.

9.1.14.1 Business overview

9.1.14.2 Products and services

9.1.15 Bayer AG

9.1.15.1 Business overview

9.1.15.2 Products and services

9.2 Strategic Developments in the Global Biopharmaceuticals Market

9.2.1 Mergers and acquisitions

9.2.2 Partnership/Collaboration

9.2.3 Geographical expansion

9.2.4 Product launch

9.2.5 Others

Chapter 10. Appendix

10.1 List of Abbreviations





LIST OF TABLES

TABLE 1 SPECIFIC PRIMARY AND SECONDARY SOURCES USED FOR THIS PUBLICATION

TABLE 2 GLOBAL BIOPHARMACEUTICALS MARKET BREAKDOWN SNAPSHOT

TABLE 3 DRIVERS FOR THE MARKET: IMPACT ANALYSIS

TABLE 4 RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS

TABLE 5 GLOBAL BIOPHARMACEUTICALS MARKET BREAKDOWN BY TYPE, $M (2011 - 2014)

TABLE 6 GLOBAL BIOPHARMACEUTICALS MARKET BREAKDOWN BY TYPE, $M (2015 - 2020)

TABLE 7 GLOBAL BIOPHARMACEUTICALS MARKET BREAKDOWN BY APPLICATION, $M (2011 - 2014)

TABLE 8 GLOBAL BIOPHARMACEUTICALS MARKET BREAKDOWN BY APPLICATION, $M (2015 - 2020)

TABLE 9 GLOBAL BIOPHARMACEUTICALS MARKET BREAKDOWN BY REGION, $M (2011 - 2014)

TABLE 10 GLOBAL BIOPHARMACEUTICALS MARKET BREAKDOWN BY REGION, $M (2015 - 2020)

TABLE 11 GLOBAL MONOCLONAL ANTIBODIES MARKET BREAKDOWN BY REGION $M (2011-2014)

TABLE 12 GLOBAL MONOCLONAL ANTIBODIES MARKET BREAKDOWN BY REGION, $M (2015-2020)

TABLE 13 GLOBAL RECOMBINANT HUMAN INSULIN MARKET BREAKDOWN BY REGION, $M (2011 - 2014)

TABLE 14 GLOBAL RECOMBINANT HUMAN INSULIN MARKET BREAKDOWN BY REGION, $M (2015 - 2020)

TABLE 15 GLOBAL COLONY STIMULATING FACTOR MARKET BREAKDOWN BY REGION, $M (2011-2014)

TABLE 16 GLOBAL COLONY STIMULATING FACTOR MARKET BREAKDOWN BY REGION, $M (2015-2020)

TABLE 17 GLOBAL ERYTHROPOIETIN MARKET BREAKDOWN BY REGION, $M (2011 - 2014)

TABLE 18 GLOBAL ERYTHROPOIETIN MARKET BREAKDOWN BY REGION, $M (2015 - 2020)

TABLE 19 GLOBAL VACCINES MARKET BREAKDOWN BY REGION, $M (2011-2014)

TABLE 20 GLOBAL VACCINES MARKET BREAKDOWN BY REGION, $M (2015-2020)

TABLE 21 GLOBAL GROWTH HORMONES MARKET BREAKDOWN BY REGION, $M (2011-2014)

TABLE 22 GLOBAL GROWTH HORMONES MARKET BREAKDOWN BY REGION, $M (2015-2020)

TABLE 23 GLOBAL INTERFERONS MARKET BREAKDOWN BY REGION, $M (2011-2014)

TABLE 24 GLOBAL INTERFERONS MARKET BREAKDOWN BY REGION, $M (2015-2020)

TABLE 25 GLOBAL RECOMBINANT PROTEINS MARKET BREAKDOWN BY REGION, $M (2011-2014)

TABLE 26 GLOBAL RECOMBINANT PROTEINS MARKET BREAKDOWN BY REGION, $M (2015-2020)

TABLE 27 GLOBAL PURIFIED PROTEINS MARKET BREAKDOWN BY REGION, $M (2011-2014)

TABLE 28 GLOBAL PURIFIED PROTEINS MARKET BREAKDOWN BY REGION, $M (2015-2020)

TABLE 29 GLOBAL ONCOLOGY BIOPHARMACEUTICALS MARKET BREAKDOWN BY REGION, $M (2011 - 2014)

TABLE 30 GLOBAL ONCOLOGY BIOPHARMACEUTICALS MARKET BREAKDOWN BY REGION, $M (2015 - 2020)

TABLE 31 GLOBAL INFLAMMATORY AND INFECTIOUS DISEASES BIOPHARMACEUTICALS MARKET BREAKDOWN BY REGION, $M (2011 - 2014)

TABLE 32 GLOBAL INFLAMMATORY AND INFECTIOUS DISEASES BIOPHARMACEUTICALS MARKET BREAKDOWN BY REGION, $M (2015 - 2020)

TABLE 33 GLOBAL METABOLIC DISORDERS BIOPHARMACEUTICALS MARKET BREAKDOWN BY REGION, $M (2011 - 2014)

TABLE 34 GLOBAL METABOLIC DISORDERS BIOPHARMACEUTICALS MARKET BREAKDOWN BY REGION, $M (2015 - 2020)

TABLE 35 GLOBAL NEUROLOGICAL DISORDERS BIOPHARMACEUTICALS MARKET BREAKDOWN BY REGION, $M (2011 - 2014)

TABLE 36 GLOBAL NEUROLOGICAL DISORDERS BIOPHARMACEUTICALS MARKET BREAKDOWN BY REGION, $M (2015 - 2020)

TABLE 37 GLOBAL CARDIOVASCULAR BIOPHARMACEUTICALS MARKET BREAKDOWN BY REGION, $M (2011 - 2014)

TABLE 38 GLOBAL CARDIOVASCULAR BIOPHARMACEUTICALS MARKET BREAKDOWN BY REGION, $M (2015 - 2020)

TABLE 39 NORTH AMERICA BIOPHARMACEUTICALS MARKET BREAKDOWN BY TYPE, $M (2011 - 2014)

TABLE 40 NORTH AMERICA BIOPHARMACEUTICALS MARKET BREAKDOWN BY TYPE, $M (2015 - 2020)

TABLE 41 NORTH AMERICA BIOPHARMACEUTICALS MARKET BREAKDOWN BY APPLICATION, $M (2011 - 2014)

TABLE 42 NORTH AMERICA BIOPHARMACEUTICALS MARKET BREAKDOWN BY APPLICATION, $M (2015 - 2020)

TABLE 43 NORTH AMERICA BIOPHARMACEUTICALS MARKET BREAKDOWN BY COUNTRY, $M (2011 - 2014)

TABLE 44 NORTH AMERICA BIOPHARMACEUTICALS MARKET BREAKDOWN BY COUNTRY, $M (2015 - 2020)

TABLE 45 EUROPE BIOPHARMACEUTICALS MARKET BREAKDOWN BY TYPE, $M (2011 - 2014)

TABLE 46 EUROPE BIOPHARMACEUTICALS MARKET BREAKDOWN BY TYPE, $M (2015 - 2020)

TABLE 47 EUROPE BIOPHARMACEUTICALS MARKET BREAKDOWN BY APPLICATION, $M (2011 - 2014)

TABLE 48 EUROPE BIOPHARMACEUTICALS MARKET BREAKDOWN BY APPLICATION, $M (2015 - 2020)

TABLE 49 EUROPE BIOPHARMACEUTICALS MARKET BREAKDOWN BY COUNTRY, $M (2011 - 2014)

TABLE 50 EUROPE BIOPHARMACEUTICALS MARKET BREAKDOWN BY COUNTRY, $M (2015 - 2020)

TABLE 51 ASIA BIOPHARMACEUTICALS MARKET BREAKDOWN BY TYPE, $M (2011 - 2014)

TABLE 52 ASIA BIOPHARMACEUTICALS MARKET BREAKDOWN BY TYPE, $M (2015 - 2020)

TABLE 53 ASIA BIOPHARMACEUTICALS MARKET BREAKDOWN BY APPLICATION, $M (2011 - 2014)

TABLE 54 ASIA BIOPHARMACEUTICALS MARKET BREAKDOWN BY APPLICATION, $M (2015 - 2020)

TABLE 55 ASIA BIOPHARMACEUTICALS MARKET BREAKDOWN BY COUNTRY, $M (2011 - 2014)

TABLE 56 ASIA BIOPHARMACEUTICALS MARKET BREAKDOWN BY COUNTRY, $M (2015 - 2020)

TABLE 57 REST OF THE WORLD BIOPHARMACEUTICALS MARKET BREAKDOWN BY TYPE, $M (2011 - 2014)

TABLE 58 REST OF THE WORLD BIOPHARMACEUTICALS MARKET BREAKDOWN BY TYPE, $M (2015 - 2020)

TABLE 59 REST OF THE WORLD BIOPHARMACEUTICALS MARKET BREAKDOWN BY APPLICATION, $M (2011 - 2014)

TABLE 60 REST OF THE WORLD BIOPHARMACEUTICALS MARKET BREAKDOWN BY APPLICATION, $M (2015 - 2020)

TABLE 61 REST OF THE WORLD BIOPHARMACEUTICALS MARKET BREAKDOWN BY COUNTRY, $M (2011 - 2014)

TABLE 62 REST OF THE WORLD BIOPHARMACEUTICALS MARKET BREAKDOWN BY COUNTRY, $M (2015 - 2020)

TABLE 63 ABBVIE INC. - KEY FACTS

TABLE 64 SANOFI - KEY FACTS

TABLE 65 ELI LILLY AND COMPANY- KEY FACTS

TABLE 66 PFIZER INC. - KEY FACTS

TABLE 67 ABBOTT LABORATORIES- KEY FACTS

TABLE 68 ASTRAZENECA PLC - KEY FACTS

TABLE 69 NOVARTIS AG - KEY FACTS

TABLE 70 BIOGEN IDEC - KEY FACTS

TABLE 71 AMGEN INC. - KEY FACTS

TABLE 72 BRISTOL-MYERS SQUIBB COMPANY- KEY FACTS

TABLE 73 GLAXO SMITH KLINE PLC- KEY FACTS

TABLE 74 JOHNSON and JOHNSON SERVICES INC. - KEY FACTS

TABLE 75 F. HOFFMANN-LA ROCHE LTD - KEY FACTS

TABLE 76 MERCK and CO.,INC. - KEY FACTS

TABLE 77 BAYER AG - KEY FACTS



LIST OF FIGURES

FIG 1 RESEARCH SCOPE FOR GLOBAL BIOPHARMACEUTICALS MARKET

FIG 2 RESEARCH METHODOLOGY FOR GLOBAL BIOPHARMACEUTICALS MARKET

FIG 3 AGING POPULATION AS A PERCENTAGE OF TOTAL POPULATION IN MAJOR COUNTRIES

FIG 4 GLOBAL BIOPHARMACEUTICALS MARKET SIZE BY TYPE, $M (2011-2020)

FIG 5 GLOBAL BIOPHARMACEUTICALS MARKET SHARE, BY TYPE (2014 AND 2020)

FIG 6 GLOBAL BIOPHARMACEUTICALS MARKET SIZE BY APPLICATION, $M (2011-2020)

FIG 7 GLOBAL BIOPHARMACEUTICALS MARKET SHARE, BY APPLICATION (2014 AND 2020)

FIG 8 GLOBAL BIOPHARMACEUTICALS MARKET SIZE BY REGION, $M (2011-2020)

FIG 9 GLOBAL BIOPHARMACEUTICALS MARKET SHARE, BY REGION (2014 AND 2020)

FIG 10 BIOPHARMACEUTICALS MARKET SEGMENTATION BASED ON TYPE

FIG 11 GLOBAL MONOCLONAL ANTIBODIES MARKET SHARE, BY REGION (2014 AND 2020)

FIG 12 GLOBAL RECOMBINANT HUMAN INSULIN MARKET SHARE, BY REGION (2014 AND 2020)

FIG 13 GLOBAL COLONY STIMULATING FACTOR MARKET SHARE BY REGION (2014 AND 2020)

FIG 14 GLOBAL ERYTHROPOIETIN MARKET SHARE, BY REGION (2014 AND 2020)

FIG 15 GLOBAL VACCINES MARKET SHARE, BY REGION (2014 AND 2020)

FIG 16 GLOBAL GROWTH HORMONES MARKET SHARE, BY REGION (2014 AND 2020)

FIG 17 GLOBAL INTERFERONS MARKET SHARE, BY REGION (2014 AND 2020)

FIG 18 GLOBAL RECOMBINANT PROTEINS MARKET SHARE, BY REGION (2014 AND 2020)

FIG 19 GLOBAL PURIFIED PROTEINS MARKET SHARE BY REGION (2014 AND 2020)

FIG 20 BIOPHARMACEUTICALS MARKET SEGEMTATION BASED ON APPLICATION

FIG 21 GLOBAL ONCOLOGY BIOPHARMACEUTICALS MARKET SHARE, BY REGION (2014 AND 2020)

FIG 22 GLOBAL INFLAMMATORY AND INFECTIOUS DISEASES BIOPHARMACEUTICALS MARKET SHARE, BY REGION (2014 AND 2020)

FIG 23 GLOBAL METABOLIC DISORDERS BIOPHARMACEUTICALS MARKET SHARE, BY REGION (2014 AND 2020)

FIG 24 GLOBAL NEUROLOGICAL DISORDERS BIOPHARMACEUTICALS MARKET SHARE, BY REGION (2014 AND 2020)

FIG 25 GLOBAL CARDIOVASCULAR BIOPHARMACEUTICALS MARKET SHARE, BY REGION (2014 AND 2020)

FIG 26 GLOBAL BIOPHARMACEUTICALS MARKET, BY COUNTRY (2020)

FIG 27 NORTH AMERICA BIOPHARMACEUTICALS MARKET SHARE, BY TYPE (2014 AND 2020)

FIG 28 NORTH AMERICA BIOPHARMACEUTICALS MARKET SHARE, BY APPLICATION (2014 AND 2020)

FIG 29 NORTH AMERICA BIOPHARMACEUTICALS MARKET SHARE, BY COUNTRY (2014 AND 2020)

FIG 30 EUROPE BIOPHARMACEUTICALS MARKET SHARE BY TYPE (2014 AND 2020)

FIG 31 EUROPE BIOPHARMACEUTICALS MARKET SHARE, BY APPLICATION (2014 AND 2020)

FIG 32 EUROPE BIOPHARMACEUTICALS MARKET SHARE, BY COUNTRY (2014 AND 2020)

FIG 33 ASIA BIOPHARMACEUTICALS MARKET SHARE, BY TYPE (2014 AND 2020)

FIG 34 ASIA BIOPHARMACEUTICALS MARKET SHARE, BY APPLICATION (2014 AND 2020)

FIG 35 ASIA BIOPHARMACEUTICALS MARKET SHARE, BY COUNTRY (2014 AND 2020)

FIG 36 REST OF THE WORLD BIOPHARMACEUTICALS MARKET SHARE, BY TYPE (2014 AND 2020)

FIG 37 REST OF THE WORLD BIOPHARMACEUTICALS MARKET SHARE, BY APPLICATION (2014 AND 2020)

FIG 38 REST OF THE WORLD BIOPHARMACEUTICALS MARKET SHARE, BY COUNTRY (2014 AND 2020)

FIG 39 PORTER'S FIVE FORCES OF COMPETITIVE POSITION ANALYSIS

FIG 40 GLOBAL BIOPHARMACEUTICALS MARKET SHARE, BY COMPANY (2014)

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Single-use Bioreactor Market by Product, Cell, Technology, Application, End User - Global Forecast to 2021

Single-use Bioreactor Market by Product, Cell, Technology, Application, End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global single-use bioreactors market is projected to reach USD 1,085.7 million by 2021 from USD 408.4 million in 2016, growing at a CAGR of 21.6% during the forecast period (2016–2021). In this report, ...

Global Biopharmaceuticals Market Growth, Trends & Forecasts (2016 - 2021)

Global Biopharmaceuticals Market Growth, Trends & Forecasts (2016 - 2021)

  • $ 4250
  • Industry report
  • September 2016
  • by Mordor Intelligence LLP

In the year 2015, the global market for biopharmaceuticals was valued at USD 176.9 billion. It is estimated at USD 192.2 million for the year 2016 and is projected to reach USD 291 billion by the yea ...

Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010 to 2016

Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010 to 2016

  • $ 2995
  • Industry report
  • September 2016
  • by Currentpartnering

The Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2016 report provides comprehensive understanding and unprecedented access to the co-development deals and ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.